Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 1;8(2):300-301.
doi: 10.1001/jamaoncol.2021.6764.

Assessment of Response to a Third Dose of the SARS-CoV-2 BNT162b2 mRNA Vaccine in Patients With Solid Tumors Undergoing Active Treatment

Yakir Rottenberg  1   2 , Albert Grinshpun  3 , Iddo Z Ben-Dov  4   2 , Esther Oiknine Djian  5   2 , Dana G Wolf  5   2 , Luna Kadouri  1   2
Affiliations

Assessment of Response to a Third Dose of the SARS-CoV-2 BNT162b2 mRNA Vaccine in Patients With Solid Tumors Undergoing Active Treatment

Yakir Rottenberg et al. JAMA Oncol. .

Abstract

This cohort study evaluates the short-term humoral response to a third dose of the SARS-CoV-2 BNT162b2 vaccine in patients undergoing acute systemic therapy for solid tumors.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Grinshpun reported support from the Israel Science Foundation (grant 3020/20) and the 2020 Conquer Cancer Israel Cancer Research Fund Career Development Award. Dr Kadouri reported support from Eli Lilly outside the submitted work. No other disclosures were reported.

Figures

Figure.
Figure.. Serologic Response to a Third Dose of the SARS-CoV-2 BNT162b2 mRNA Vaccine in Patients With Cancer Undergoing Active Treatment
Comparison between antibody levels after the second dose and the third booster dose of BNT162b2 (Pfizer-BioNTech) in patients treated with chemotherapy and nonchemotherapy regimens. Measurements less than 12 AU/mL are considered negative, 12 to 19 AU/mL are equivocal, and greater than 19 are positive (dashed line). Levels above 60 AU/mL were shown to be protective. The upper antibody titer limit was capped at more than 400 AU/mL; thus, the titer differences may be higher than those recorded. The titer increment in both groups is statistically significant at P < .001.
See this image and copyright information in PMC

References

    1. Brar G, Pinheiro LC, Shusterman M, et al. . COVID-19 severity and outcomes in patients with cancer: a matched cohort study. J Clin Oncol. 2020;38(33):3914-3924. doi:10.1200/JCO.20.01580 - DOI - PMC - PubMed
    1. Aschele C, Negru ME, Pastorino A, et al. . Incidence of SARS-CoV-2 infection among patients undergoing active antitumor treatment in Italy. JAMA Oncol. 2021;7(2):304-306. doi:10.1001/jamaoncol.2020.6778 - DOI - PMC - PubMed
    1. Grinshpun A, Rottenberg Y, Ben-Dov IZ, Djian E, Wolf DG, Kadouri L. Serologic response to COVID-19 infection and/or vaccine in cancer patients on active treatment. ESMO Open. 2021;6(6):100283. doi:10.1016/j.esmoop.2021.100283 - DOI - PMC - PubMed
    1. Herishanu Y, Avivi I, Aharon A, et al. . Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137(23):3165-3173. doi:10.1182/blood.2021011568 - DOI - PMC - PubMed
    1. Bar-On YM, Goldberg Y, Mandel M, et al. . Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N Engl J Med. 2021;385(15):1393-1400. doi:10.1056/NEJMoa2114255 - DOI - PMC - PubMed